Subscribe to RSS
DOI: 10.1055/s-0030-1256511
© Georg Thieme Verlag KG Stuttgart · New York
Treatment of a benign colorectal anastomotic stricture with a biodegradable stent
E. TothMD, PhD
Endoscopy Unit
Department of Clinical
Sciences
Skåne University Hospital
Lund
University
20502 Malmö
Sweden
Fax: +46-40-338699
Email: ervin.toth@med.lu.se
Publication History
Publication Date:
11 August 2011 (online)
It is routine practice to use metal stents in the treatment of malign obstructions in the lower gastrointestinal tract [1]. However, metal stents are not suitable for benign conditions. Recently, treatment with biodegradable stents has been implemented for non-malignant diseases in the upper gastrointestinal tract [2] [3], but there is no case in the literature reporting on the use of biodegradable stents for benign conditions in the lower gastrointestinal tract. Here we describe a case with a benign stricture in a colorectal anastomosis, treated with a biodegradable stent.
A 68-year-old man underwent sigmoid stoma reversal after Hartmann’s procedure (for perforated diverticulitis). The patient developed a symptomatic stricture in the colorectal anastomosis ([Fig. 1]), and biopsies were benign. Despite three endoscopic dilations, the patient suffered from repeated symptomatic stricture recurrence.
Due to significant co-morbidity, the patient was not suitable for surgical treatment. As an alternative approach, a self-expanding biodegradable esophageal stent (SX-Ella stent; ELLA-CS, Hradec Kralove, Czech Republic) was chosen. The lumen of the stricture was less than 5 mm and was dilated up to 12 mm. The biodegradable stent was deployed in the middle of the stricture using a guide wire ([Fig. 2]). The position of the stent was monitored 4 days later and the lumen further dilated to 15 mm. The stent position was monitored 6 weeks after deployment; the stent was shown to be partially reabsorbed ([Fig. 3]). The patient was still asymptomatic and a colonoscopy revealed complete biodegradation of the stent 5 months later ([Fig. 4 a]). At this time, the lumen had reduced to 8 mm ([Fig. 4 b]) and was therefore dilated up to 18 mm. A follow-up was performed 2 years later, which revealed that the patient had no clinical symptoms although the size of the lumen had reduced.
This unique case demonstrates that treatment with biodegradable stents is also feasible in patients with benign strictures in the lower gastrointestinal tract.
Endoscopy_UCTN_Code_TTT_1AQ_2AF
Competing interests: None
#References
- 1 Lee J H, Ross W A, Davila R et al. Self-expandable metal stents (SEMS) can serve as a bridge to surgery or as a definitive therapy in patients with an advanced stage of cancer: clinical experience of a tertiary center. Dig Dis Sci. 2010; 55 3530-3536
- 2 Vandenplas Y, Hauser B, Devreker T et al. A degradable esophageal stent in the treatment of a corrosive esophageal stenosis in a child. Endoscopy. 2009; 42 E132-E133
- 3 Repici A, Vleggaar F P, Hassan C et al. Efficacy and safety of biodegradable stents for refractory benign esophageal strictures: the BEST (Biodegradable Esophageal Stent) study. Gastrointest Endosc. 2010; 72 927-934
E. TothMD, PhD
Endoscopy Unit
Department of Clinical
Sciences
Skåne University Hospital
Lund
University
20502 Malmö
Sweden
Fax: +46-40-338699
Email: ervin.toth@med.lu.se
References
- 1 Lee J H, Ross W A, Davila R et al. Self-expandable metal stents (SEMS) can serve as a bridge to surgery or as a definitive therapy in patients with an advanced stage of cancer: clinical experience of a tertiary center. Dig Dis Sci. 2010; 55 3530-3536
- 2 Vandenplas Y, Hauser B, Devreker T et al. A degradable esophageal stent in the treatment of a corrosive esophageal stenosis in a child. Endoscopy. 2009; 42 E132-E133
- 3 Repici A, Vleggaar F P, Hassan C et al. Efficacy and safety of biodegradable stents for refractory benign esophageal strictures: the BEST (Biodegradable Esophageal Stent) study. Gastrointest Endosc. 2010; 72 927-934
E. TothMD, PhD
Endoscopy Unit
Department of Clinical
Sciences
Skåne University Hospital
Lund
University
20502 Malmö
Sweden
Fax: +46-40-338699
Email: ervin.toth@med.lu.se